COMMUNIQUÉS West-GlobeNewswire

Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
13/05/2026
Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using [...]
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
13/05/2026
Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL) 58.3 [...]
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
13/05/2026
On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan- [...]
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected [...]
Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
13/05/2026
REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for [...]
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
13/05/2026
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash [...]
Park Dental Partners Announces First Quarter 2026 Results
13/05/2026
MINNEAPOLIS, May 13, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) and affiliated dental practices (“Park Dental Partners,” “we,” “our,” “us,” or the “Company”) today reported its first-quarter [...]
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
13/05/2026
- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form of brilaroxazine in [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
13/05/2026
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial [...]
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
13/05/2026
100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to tegoprubart for the [...]
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
13/05/2026
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 Spero maintains its cash runway [...]
Bionano Reports First Quarter 2026 Results and Provides a Business Update
13/05/2026
Conference call today, May 13, 2026, at 4:30 PM ET SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The [...]
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
13/05/2026
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is the next evolution of inflammasome [...]
Assemblée Générale Mixte du 3 juin 2026
13/05/2026
Châtillon, France, le 13 mai 2026 Assemblée Générale Mixte du 3 juin 2026 Modalités de mise à disposition des informations et documents préparatoires à l’Assemblée Générale Mixte DBV Technologies (Euronext : DBV – ISIN [...]
Aptose Reports First Quarter 2026 Results
13/05/2026
SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based [...]
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
13/05/2026
Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical [...]
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
13/05/2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics [...]
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
13/05/2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as [...]
Management team’s 2025 market-based Options have vested
13/05/2026
Share price increase from $6 to $30 triggers full vesting NEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that 2025 employee stock options [...]

Pages